Aizen Therapeutic
San Diego
About Aizen Therapeutic
Aizen Therapeutics operates as a biotechnology firm focusing on the discovery of Mirror Peptides, synthetic structures composed entirely of D-amino acids designed to expand therapeutic options beyond natural proteins. The company’s DaX™ platform, developed by Caltech Professor David Van Valen, leverages generative AI along with guided diffusion, computational binding models, and GPU compute to engineer novel peptide structures that bind clinical targets. This AI-driven process enables design-build-test cycles in roughly four weeks, with validated hit rates that exceed conventional benchmarks; the platform also supports multi-objective optimization, balancing traits like specificity, half-life, and solubility simultaneously. Aizen advances its pipeline through stages such as discovery, IND-enabling studies, and Phase 1 trials across areas including neurological disorders, oncology, and genetic diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $13.0M
- Funding stage: Seed
- Last round: Seed (Nov 2024)
- Website: aizentx.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biopharma, Biotechnology, Health Care, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/aizen-therapeutic-93401 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.